The Chemours Company

NYSE:CC Voorraadrapport

Marktkapitalisatie: US$2.8b

Chemours Balans Gezondheid

Financiële gezondheid criteriumcontroles 1/6

Chemours heeft een totaal eigen vermogen van $659.0M en een totale schuld van $4.0B, wat de schuld-eigenvermogensverhouding op 605.8% brengt. De totale activa en totale passiva bedragen respectievelijk $7.5B en $6.8B. De EBIT Chemours is $489.0M waardoor de rentedekking 1.9 is. Het heeft contanten en kortetermijnbeleggingen van $596.0M.

Belangrijke informatie

605.8%

Verhouding schuld/eigen vermogen

US$3.99b

Schuld

Rente dekkingsratio1.9x
ContantUS$596.00m
AandelenUS$659.00m
Totaal verplichtingenUS$6.80b
Totaal activaUS$7.46b

Recente financiële gezondheidsupdates

Chemours (NYSE:CC) Takes On Some Risk With Its Use Of Debt

Jul 18
Chemours (NYSE:CC) Takes On Some Risk With Its Use Of Debt

Recent updates

Chemours' (NYSE:CC) Earnings Offer More Than Meets The Eye

Nov 12
Chemours' (NYSE:CC) Earnings Offer More Than Meets The Eye

Is It Too Late To Consider Buying The Chemours Company (NYSE:CC)?

Sep 25
Is It Too Late To Consider Buying The Chemours Company (NYSE:CC)?

Chemours: We're Back Down To Trough And A 'BUY'

Sep 01

Chemours: Upside After Irregularities, Good 2024-2026E

Jun 11

The Chemours Company's (NYSE:CC) Low P/S No Reason For Excitement

May 30
The Chemours Company's (NYSE:CC) Low P/S No Reason For Excitement

Drama At The Chemours Company Opens The Door For Upside

Mar 29

The Chemours Company (NYSE:CC) Not Doing Enough For Some Investors As Its Shares Slump 37%

Mar 01
The Chemours Company (NYSE:CC) Not Doing Enough For Some Investors As Its Shares Slump 37%

Chemours: The Case Amidst Board Trouble, I Say Buy The Weakness

Feb 29

Chemours (NYSE:CC) Has Announced A Dividend Of $0.25

Feb 17
Chemours (NYSE:CC) Has Announced A Dividend Of $0.25

Chemours: Technological Innovation Presents Excellent Opportunities For Growth

Dec 23

Chemours (NYSE:CC) Will Pay A Dividend Of $0.25

Oct 30
Chemours (NYSE:CC) Will Pay A Dividend Of $0.25

The Chemours Company (NYSE:CC) Shares Could Be 21% Above Their Intrinsic Value Estimate

Oct 28
The Chemours Company (NYSE:CC) Shares Could Be 21% Above Their Intrinsic Value Estimate

Chemours: Volatile Bottom Line Needs Consistency

Oct 06

The Chemours Company: Portfolio Optimization Resulting In Compounding Growth

Sep 19

Chemours (NYSE:CC) Takes On Some Risk With Its Use Of Debt

Jul 18
Chemours (NYSE:CC) Takes On Some Risk With Its Use Of Debt

Is There An Opportunity With The Chemours Company's (NYSE:CC) 48% Undervaluation?

Jul 03
Is There An Opportunity With The Chemours Company's (NYSE:CC) 48% Undervaluation?

The Chemours Company: On A Nice Run

Jul 03

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $3.1B ) CC } overtreffen de korte termijn passiva ( $1.8B ).

Langlopende schulden: De kortetermijnactiva van CC ( $3.1B ) dekken de langetermijnschulden ( $5.0B ) niet.

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 515.3% ) CC wordt als hoog beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van CC is de afgelopen 5 jaar gestegen van 486% naar 605.8%.

Schuldendekking: De operationele kasstroom van CC is negatief, waardoor de schuld niet goed gedekt is.

Rentedekking: De rentebetalingen van CC op haar schulden worden niet goed gedekt door EBIT ( 1.9 x dekking).

Balans

Ontdek gezonde bedrijven

7D

1Y

7D

1Y

7D

1Y